Article: MARKETING RIGHTS FOR NOVARTIS INDIA CANCER DRUG WITHDRAWN.

Article: Exclusive marketing rights for Novartis' ...
PTI - The Press Trust of India Ltd.;  February 23, 2006 ;     661 words ...Exclusive marketing rights for Novartis' cancer drug withdrawn New Delhi ... said the exclusive marketing rights that had been granted to it for cancer drug Gleevec by the government ... of the exclusive marketing rights has been published ...

Article: U.S. BIOSCIENCE GAINS EUROPEAN MARKETING RIGHTS TO ...
PR Newswire;  November 19, 1991 ;     626 words ...U.S. BIOSCIENCE GAINS EUROPEAN MARKETING RIGHTS TO OVARIAN CANCER DRUG WEST CONSHOHOCKEN, Pa., Nov. 19 /PRNewswire ... the acquisition from Rhone-Poulenc Rorer of marketing rights to altretamine in specific Western European ...

Article: Roche obtains overseas marketing rights to ...
AP Worldstream;  July 8, 2003 ;     349 words ... ... Dateline: ZURICH Swiss pharmaceutical company Roche Holding AG said Tuesday it obtained the non-U.S. marketing rights to cancer-treatment Avastin from Genentech Inc. Two months ago, Genentech, of South San Francisco, California ...

Article: Oxford BioMedica secures EU boost for cancer drug ; ...
The Independent - London;  December 9, 2006 ;     520 words ... ... European Union, securing it exclusive 10-year marketing rights for its key cancer drug. Its shares rose 13 per cent on the news yesterday ... 000 people in the EU. It affords exclusive marketing rights for a certain period. The agreement will give ...

Article: DRAXIS Health Inc. Acquires Canadian Rights To Cancer ...
PR Newswire;  January 6, 1997 ;     700+ words ... ... Mylan Laboratories Inc. (NYSE: MYL) of Morgantown, West Virginia, the exclusive Canadian marketing rights to the Mylan formulation of the cancer drug, paclitaxel, used in the treatment of refractory breast and ovarian cancer. Paclitaxel ...

Article: AmSwiss imports 'orphaned' cancer drug to Canada. ...
PR Newswire;  November 30, 1988 ;     700+ words ... ... IMPORTS ORPHANED' CANCER DRUG TO CANADA VANCOUVER ... acquired the Canadian marketing rights for DBD (dibromodulcitol ... proven European anti-cancer drug with relatively few ... than any other anti-cancer drug. Based on these results ...

Article: JAPAN'S ONCOLYS TEAMS WITH TAIWAN'S MEDIGEN FOR CANCER ...
AsiaPulse News;  March 6, 2008 ;     700+ words ... ... to further the development of its cancer drug Telomelysin. Oncolys will license development and marketing rights to Medigen for Telomelysin in Asian ... the ultimate goal of selling the marketing rights to a major pharmaceutical firm ...